Sphingosine-1-phosphate (S1P) is a crucial regulator in vascular inflammation. Our 
| INTRODUCTION
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) consisted of granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) and microscopic polyangiitis (MPA). 1 AAV is characterized by pauci-immune necrotizing small vessel vasculitis which principally involves glomerular endothelial cells (GEnCs) injury, and circulating autoantibodies against myeloperoxidase (MPO) as well as proteinase 3 (PR3). 2, 3 MPO-ANCA was reported to induce GEnC activation directly in AAV. 4 The major sphingolipid metabolite, sphingosine-1-phosphate (S1P), is an important regulator in vascular inflammation. S1P and its five G-protein-coupled receptors (GPCRs), S1PR1-5, are implicated in diverse vascular inflammatory conditions. 5 Our recent studies reported that the circulating levels of S1P and the renal expression of S1PRs were associated with disease activity and renal involve-
ment of AAV, 6 and S1P participated in GEnC activation induced by MPO-ANCA-positive immunoglobulin (Ig)G via S1PR2-5. 7 However, the downstream signalling pathways of S1P in this process are still not fully clear.
Rho guanosine triphosphatases (GTPases) mediate diverse biological responses including morphogenesis, chemotaxis and cell cycle progression. 8 It was reported that Rho GTPases, especially Rac1 and RhoA, could regulate endothelial barrier function in response to S1P
and its receptors. S1P of physiological level causes the activation of S1PR1, resulting in protection of the endothelial barrier function by inducing the activation of the Rac1 signalling pathway, whereas excessive S1P will bind to S1PR2/S1PR3, leading to the activation of RhoA as well as the disruption of endothelial barrier function. [9] [10] [11] In view of the potential role of Rho GTPases in regulating endothelial barrier function, we hypothesized that Rho GTPases, RhoA and Rac1 in particular, might contribute to S1P-enhanced GEnC activation in the presence of MPO-ANCA-positive IgG.
| MATERIALS AND METHODS

| Reagents
See the "Supporting Information Data S1."
| Cell culture
Primary human glomerular endothelial cells (GEnC; ScienCell, San Diego, CA, USA) were cultured according to the manufacturer's instructions.
| IgG preparation
MPO-ANCA-positive IgGs and normal IgGs were prepared as previously described 7 (detailed in the "Supporting Information Data S1").
| Measurement of Rho GTPase activation
Rac1 and RhoA activation assays were performed following the manufacturer's instructions (Cytoskeleton, Denver, CO, USA).
| Measurement of GEnC activation
As biomarkers of endothelial cell activation, levels of soluble vascular cell adhesion molecule-1(sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) in the GEnC supernatants were tested with commercially available ELISA kits (R&D, Minneapolis, MN, USA). 
| Statistical analysis
The normality of our data was evaluated by skewness and kurtosis (both the absolute values were less than 3). Differences were considered statistically significant if P < .05 (detailed in the "Supporting Information Data S1"). junctions. 13 Loss of endothelial cell-cell contact and increased permeability also facilitates leukocyte transendothelial migration and damage to endothelium, which is of vital importance in AAV. 14 
Contrary to
RhoA, Rac1 activated by S1PR1 enhances endothelial barrier function by inducing reorganization of the actin cytoskeleton as well as affecting the formation of lamellipodia and membrane ruffles. 15 In the present study, we found that RhoA activated by S1PR2-5 dominated the S1P- In conclusion, our current study demonstrated that Rho GTPases signalling pathways were involved in S1P-enhanced GEnCs activation with MPO-ANCA-positive IgG. RhoA activated by S1PR2-5 dominated the S1P-induced GEnC activation in the presence of MPO-ANCA-positive IgG, while Rac1 activated by S1PR1 exerted opposite effect during this process. These findings provide us with more clues to determine the role of and Rho GTPases and S1P in the development of AAV.
